Company: ACBM
Filing Date: 2025-07-11
Form Type: 10-Q
Source: 0001640334-25-001169
Chunk: 19

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-11
Form: 10-Q
Item: Item 1
Chunk 19
---
  -  -   60,042,000  60,042  32,293,739  (19,845,283 ) (11,865,279 ) 643,219                                  Amortization of deferred stock compensation  -   -   -   -   -   3,928,100   -   3,928,100 Imputed interest on related party loans  -   -   -   -   211   -   -   211 Net loss  -   -   -   -   -   -   (3,996,643 )  (3,996,643 )                                 Balance, June 30, 2022  -  -   60,042,000  60,042  32,293,950  (15,917,183 ) (15,861,922 ) 574,887                                  Amortization of deferred stock compensation  -   -   -   -   -   3,928,100   -   3,928,100 Imputed interest on related party loans  -   -   -   -   499   -   -   499 Net loss  -   -   -   -   -   -   (4,011,322 )  (4,011,322 )                                 Balance, September 30, 2022  -  $-   60,042,000  $60,042  $32,294,449  $(11,989,083 ) $(19,873,244 ) $492,164 

The accompanying notes are an integral part of these unaudited financial statements.

 6Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Cash Flows

(Unaudited) 

   Nine Months Ended    September 30,    2023  2022        CASH FLOWS FROM OPERATING ACTIVITIES      Net loss $(8,789,333) $(11,936,762)Adjustments to reconcile net loss to net cash used